Sit Investment Associates’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.64M | Sell |
113,514
-293
| -0.3% | -$19.5K | 0.14% | 167 |
|
|
2026
Q1 | $7.15M | Sell |
113,807
-9,700
| -8% | -$675K | 0.15% | 166 |
|
|
2025
Q4 | $8.2M | Sell |
123,507
-4,609
| -4% | -$298K | 0.16% | 155 |
|
|
2025
Q3 | $8.62M | Buy |
128,116
+93
| +0.1% | +$7.36K | 0.17% | 140 |
|
|
2025
Q2 | $11.2M | Sell |
128,023
-4,812
| -4% | -$377K | 0.24% | 106 |
|
|
2025
Q1 | $9.07M | Buy |
132,835
+1,592
| +1% | +$130K | 0.21% | 123 |
|
|
2024
Q4 | $10.2M | Sell |
131,243
-3,473
| -3% | -$257K | 0.23% | 117 |
|
|
2024
Q3 | $9.03M | Buy |
134,716
+5,959
| +5% | +$489K | 0.2% | 142 |
|
|
2024
Q2 | $14.6M | Buy |
128,757
+887
| +0.7% | +$112K | 0.34% | 87 |
|
|
2024
Q1 | $17.7M | Sell |
127,870
-180
| -0.1% | -$22.6K | 0.41% | 73 |
|
|
2023
Q4 | $15.9M | Sell |
128,050
-9,055
| -7% | -$925K | 0.39% | 77 |
|
|
2023
Q3 | $12.8M | Buy |
137,105
+1,622
| +1% | +$183K | 0.35% | 82 |
|
|
2023
Q2 | $17.4M | Buy |
135,483
+486
| +0.4% | +$58.8K | 0.45% | 56 |
|
|
2023
Q1 | $15.7M | Sell |
134,997
-2,129
| -2% | -$238K | 0.43% | 65 |
|
|
2022
Q4 | $15.5M | Buy |
137,126
+4,066
| +3% | +$446K | 0.44% | 58 |
|
|
2022
Q3 | $10.7M | Sell |
133,060
-745
| -0.6% | -$63.1K | 0.32% | 92 |
|
|
2022
Q2 | $9.97M | Buy |
133,805
+2,697
| +2% | +$246K | 0.3% | 94 |
|
|
2022
Q1 | $16.8M | Buy |
131,108
+252
| +0.2% | +$27.6K | 0.45% | 64 |
|
|
2021
Q4 | $17.6M | Buy |
130,856
+6,424
| +5% | +$923K | 0.41% | 70 |
|
|
2021
Q3 | $17M | Sell |
124,432
-12,744
| -9% | -$1.61M | 0.44% | 63 |
|
|
2021
Q2 | $14.6M | Sell |
137,176
-2,124
| -2% | -$204K | 0.36% | 79 |
|
|
2021
Q1 | $12.5M | Buy |
139,300
+1,500
| +1% | +$141K | 0.33% | 87 |
|
|
2020
Q4 | $12.7M | Buy |
137,800
+27,560
| +25% | +$2.46M | 0.34% | 83 |
|
|
2020
Q3 | $11.4M | Buy |
110,240
+1,180
| +1% | +$123K | 0.33% | 86 |
|
|
2020
Q2 | $11.1M | Sell |
109,060
-15,900
| -13% | -$1.42M | 0.35% | 86 |
|
|
2020
Q1 | $8.41M | Buy |
124,960
+520
| +0.4% | +$32.4K | 0.32% | 96 |
|
|
2019
Q4 | $6.8M | Buy |
124,440
+56,640
| +84% | +$2.69M | 0.19% | 153 |
|
|
2019
Q3 | $2.53M | Buy |
67,800
+9,800
| +17% | +$381K | 0.08% | 256 |
|
|
2019
Q2 | $2.17M | Hold |
58,000
| – | – | 0.07% | 271 |
|
|
2019
Q1 | $1.73M | Buy |
58,000
+18,400
| +46% | +$647K | 0.05% | 281 |
|
|
2018
Q4 | $1.19M | Buy |
+39,600
| New | +$1.26M | 0.04% | 312 |
|
|
2017
Q3 | – | Sell |
-116,500
| Closed | -$2.13M | – | 662 |
|
|
2017
Q2 | $2.13M | Buy |
116,500
+20,900
| +22% | +$386K | 0.05% | 277 |
|
|
2017
Q1 | $2.02M | Buy |
95,600
+58,800
| +160% | +$1.15M | 0.05% | 277 |
|
|
2016
Q4 | $549K | Buy |
+36,800
| New | +$652K | 0.01% | 374 |
|
|
2016
Q3 | – | Sell |
-84,800
| Closed | -$1.68M | – | 456 |
|
|
2016
Q2 | $1.68M | Buy |
84,800
+38,400
| +83% | +$654K | 0.04% | 263 |
|
|
2016
Q1 | $788K | Buy |
+46,400
| New | +$775K | 0.01% | 337 |
|
Other funds holding DXCM
Sit Investment Associates's DXCM Position: Q2 2026 in Review
Sit Investment Associates reduced its DexCom (DXCM) stake by 0.26% in Q2 2026, selling an estimated $19.5K and leaving 113,514 shares worth $7.64M. The position accounts for 0.14% of the portfolio, ranked #167.
Sit Investment Associates first reported a position in DXCM in Q1 2016 and has held it in 36 quarters since. The position peaked at $17.7M in Q1 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Sit Investment Associates held 113,514 shares of DexCom worth $7.64M as of Q2 2026.
- Sit Investment Associates sold 293 DexCom shares in Q2 2026, an estimated $19.5K.
- DexCom made up 0.14% of Sit Investment Associates's portfolio in Q2 2026, its #167 holding.
- Sit Investment Associates first reported a position in DexCom in Q1 2016 and has held it in 36 quarters since.
- Sit Investment Associates's DexCom position peaked at $17.7M in Q1 2024.
- 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Sit Investment Associates's 13F filing for Q2 2026, filed 12 Aug 2026.